Compare Hyatt Hotels Corporation (H) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Pfizer Inc — how do they compare? Hyatt Hotels Corporation trades at $161.76 (market cap $15.02B), while Pfizer Inc trades at $28.14 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 10.6× Hyatt Hotels Corporation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Pfizer Inc for 158 Days on average.
| H | PFE | |
|---|---|---|
Market Cap | $15.02B | $158.56B |
Volume | 842,340 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $29.02 |
52-Week Low | $135.42 | $23.67 |
Typical Hold Time | 148 Days | 158 Days |
Enterprise Value | $18.93B | $210.06B |
Dividend Yield | 0.38% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $160.27, up 1.99% with recent earnings beats but faces bearish technical signals. The stock shows mixed fundamentals with a high P/E of 196.83 and modest net income margin of 1.1%, though revenue growth to $7.10B in 2025 and strategic collaborations with Delta Air Lines highlight expansion efforts. Analyst consensus is moderately bullish with a $197.77 price target, but negative cash flow trends and elevated debt levels present challenges.
Outlook remains cautious due to valuation concerns and operational headwinds, though long-term growth initiatives offer potential upside. Key risks include profit margin volatility, high leverage, and competitive pressure. Investors should weigh analyst optimism against fundamental weaknesses before positioning.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
